A Study of PRT1419 in Patients With Advanced Solid Tumors

Summary

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

Timeline

Start

2021-08-11

Primary completion

2023-02-06

Completion

2023-02-06

Drugs

Indications